8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 30, 2015
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
| | |
Delaware | 001-35006 | 93-0979187 |
(State or Other Jurisdiction
of Incorporation) | (Commission
File Number) | (IRS Employer
Identification No.) |
|
| | |
| 11500 S. Eastern Ave., Ste. 240, Henderson, NV | 89052 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (702) 835-6300
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On November 30, 2015, Spectrum Pharmaceuticals, Inc. (the “Company”) received the attached letter from the Securities and Exchange Commission (“SEC”), indicating that the SEC has concluded its investigation; no action is being taken against the Company.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
| | |
|
| | |
Exhibit No. | | Description |
99.1 | | SEC letter dated November 30, 2015 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
| Spectrum Pharmaceuticals, Inc. |
| | |
Date: December 7, 2015 | By: | /s/ Kurt A. Gustafson |
| | Kurt A. Gustafson |
| | Executive Vice President and Chief |
| | Financial Officer |
EXHIBIT INDEX |
| | |
|
| | |
Exhibit No. | | Description |
99.1 | | SEC letter dated November 30, 2015. |